# Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R

> **NCT02045368** · PHASE1 · COMPLETED · sponsor: **IGF Oncology, LLC** · enrollment: 92 (actual)

## Conditions studied

- Breast Cancer
- Brain Cancer
- Gastrointestinal Cancers
- Genitourinary Cancers
- Gynecologic Cancers
- Head and Neck Cancers
- Melanoma
- Thoracic Cancers

## Interventions

- **DRUG:** IGF-Methotrexate conjugate

## Key facts

- **NCT ID:** NCT02045368
- **Lead sponsor:** IGF Oncology, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-28
- **Primary completion:** 2016-09-30
- **Final completion:** 2016-09-30
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2019-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02045368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02045368, "Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02045368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*